Asciminib add-on

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, The University of Hong Kong

Conditions

Blastic Transformation of Chronic Myeloid LeukemiaCMLChronic Myelogenous LeukemiaHaematopoietic Stem Cell Transplant, AllogeneicHematologic DiseasesLeukemia, Myeloid ChronicPh+ Acute Lymphoblastic Leukemia (Ph+ALL)Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)

Phase 2

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

CompletedNCT03578367

Novartis PharmaceuticalsChronic Myelogenous Leukemia, CML, Hematologic Diseases +1

Start: 2018-11-22End: 2025-02-26Updated: 2026-04-21

Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

Not yet recruitingNCT07493408

The University of Hong KongBlastic Transformation of Chronic Myeloid Leukemia, Haematopoietic Stem Cell Transplant, Allogeneic, Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) +1

Start: 2026-03-30End: 2037-12-31Target: 45Updated: 2026-03-25

Related Papers

High rates of deep molecular response (DMR) in patients (pts) with chronic myeloid leukemia in chronic Phase (CML-CP) who have not achieved dmr after ≥1 year of prior imatinib (IMA) in the asciminib (ASC) monotherapy arm of the Phase 2 ASC4MORE study

Blood2025-11-03

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1<sup>T315I</sup> treated with at least 2 prior TKIs: Phase 1 final results.

2025-04-093 citations

Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study.

2024-12-186 citations

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Blood2023-11-024 citations

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Blood2022-11-158 citations

Randomized, Open-Label, Multicenter, Phase 2 Study of Asciminib (ABL001) As an Add-on to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Frontline Imatinib

Blood2019-11-134 citations

S883 COMBINATION THERAPY USING ASCIMINIB PLUS IMATINIB (IMA) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY

HemaSphere2019-06-0118 citations

S884 COMBINATION OF ASCIMINIB PLUS NILOTINIB (NIL) OR DASATINIB (DAS) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY

HemaSphere2019-06-0115 citations